Amgen Inc (AMGN) Releases Top-Line Results From ASCEND Study of Rocatinlimab

Amgen Inc. (NASDAQ:AMGN) is one of the Blue Chip Stocks to Buy with the Lowest PE Ratios. On September 8, Amgen Inc. (NASDAQ:AMGN), along with Kyowa Kirin preliminary top-line results from the ASCEND study of Rocatinlimab in moderate to severe atopic dermatitis. Rocatinlimab is an experimental T-cell therapy targeting the OX40 receptor, which aims to rebalance immune responses in AD.

The ASCEND study includes about 2,600 adults and adolescents who completed earlier ROCKET trials. The analysis is focused on adults who completed 24 weeks of Rocatinlimab in a parent trial and continued treatment for 32 additional weeks in ASCEND. Rocatinlimab was given every 4 or 8 weeks at doses of 150 mg or 300 mg.

The goal of the study was to assess the safety profile. The common side effects included upper respiratory infections, aphthous ulcers, headache, influenza, cough, and rhinitis, all of which were consistent with earlier studies. Moreover, the study also showed a low rate of treatment discontinuation due to adverse effects. In terms of efficacy, adults who responded after 24 weeks and continued Rocatinlimab showed sustained benefits at one year, with improvements seen in skin clearance, itching, disease extent, and severity.

Amgen Inc. (NASDAQ:AMGN) is a global biotechnology company that discovers, develops, manufactures, and delivers innovative medicines for serious diseases.

While we acknowledge the potential of AMGN  as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.